Severe Acute Respiratory Syndrome Coronavirus 2–Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience

Puing, Alfredo; Ho, Stephanie G Y; Frankel, Paul; Tegtmeier, Bernard; Martin, Abigail; Ross, Justine Abella; Nanayakkara, Deepa; Dickter, Jana; Seto, Tyler; Nakamura, Ryotaro; Taplitz, Randy; Dadwal, Sanjeet

doi:10.1093/infdis/jiab406

Cited by 8 publications

(14 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single-center experience of 42 cancer patients in total has been described (76% with hematological malignancy) where mild to moderate COVID-19 was treated with either bamlanivimab (83%) or casirivimab/imdevimab (17%). 9 The median time to NmAb infusion -5 days from symptom onset -was longer than in our study. Only 12% of these patients had COVID-19 deterioration requiring hospitalization --all after bamlanivimab --from which one died (2%).…”

Section: The Proportion Of Anti-sars-covcontrasting

confidence: 68%

“…Concerning hematological patients, no extensive cohort studies of COVID‐19 positive hematological patients treated with NmAbs have been published. A single‐center experience of 42 cancer patients in total has been described (76% with hematological malignancy) where mild to moderate COVID‐19 was treated with either bamlanivimab (83%) or casirivimab/imdevimab (17%) 9 . The median time to NmAb infusion ‐ 5 days from symptom onset ‐ was longer than in our study.…”

Section: Discussionmentioning

confidence: 57%

“…7,8 In literature, robust data on NmAbs effectivity in COVID-19 positive hematological patients are still lacking. 9,10 As a result, we resolved to analyze results of what at the time was dominantly the largest cohort of COVID-19 immunocompromized hematology patients treated with NmAbs-bamlanivimab or casirivimab/imdevimab.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience

Weinbergerová

Demel

Víšek

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

COVID-19 significantly impairs survival rates among hematological patients when compared to the general population. Our prospective multicentre project analyzed early administration of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies (NmAbs) -bamlanivimab (72%) and casirivimab/imdevimab (28%) -efficacy among hematological patients with early-stage COVID-19. Mortality rate was compared to a control cohort of 575 SARS-CoV-2 positive hematological patients untreated with any specific anti-COVID-19 therapy. 88 hematological patients with lymphomas, acute leukemias, and myeloma as their most frequent underlying diagnoses (72%) were evaluated with a 97 days median follow-up after NmAb administration. One third of patients (32%) were treated with an anti-CD20 monoclonal antibody before COVID-19 diagnosis. Median time between first COVID-19 symptom and NmAb administration was 2 days. When administering NmAb, 29%, 57%, 11%, 2%, and 1% of our patients had asymptomatic, mild, moderate, severe, and critical degrees of COVID-19, respectively.

show abstract

Section: The Proportion Of Anti-sars-covcontrasting

confidence: 68%

Section: Discussionmentioning

confidence: 57%

See 1 more Smart Citation

Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience

Weinbergerová

Demel

Víšek

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Data on this specific population, though minimal, are promising. In one single-center retrospective study, 42 patients with cancer in general and COVID-19 received therapeutic monoclonal antibody preparations, mostly bamlanivimab-based [ 76 ]. Of these, 5 (12%) were admitted to the hospital, with only one (2%) requiring an ICU level of care.…”

Section: Covid-19 Therapeutics In Patients With Hematologic Malignanciesmentioning

confidence: 99%

COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments

et al. 2022

View full text Add to dashboard Cite

Patients with hematologic malignancies are particularly vulnerable to infections due to underlying humoral and cellular immune dysfunction, cytotoxic chemotherapy regimens, advanced age, and the presence of comorbid conditions. Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, has become a leading cause of death globally and has disproportionally affected this high-risk population. Here, we review the cumulative evidence demonstrating worse outcomes for patients with hematologic malignancies when compared to patients with solid tumors and the general population. We examine risk factors shared with the general population (age, sex, comorbid conditions, race) and those that are cancer-specific (cytotoxic chemotherapy, progressive disease, cancer type), all of which confer an increased risk of severe COVID-19. Despite the historical exclusion of cancer patients from COVID-19 therapy trials, we review the emerging evidence that patients with hematologic malignancies benefit from specific treatments such as convalescent plasma. Although COVID-19 vaccines are significantly less effective in this patient population, encouraging results are observed in a subset of these patients after receiving a booster dose.

show abstract

“…For instant, only patients with mild to moderate Covid-19 patients who might progress to severe Covid-19 cases would recommended to receive MAb therapy. These patients usually had underlined diseases, overweight or cancer (Kim et al, 2021;Puing et al, 2021).…”

Section: Monoclonal Antibody (Mab) Against Sars-cov-2/covid-19mentioning

confidence: 99%

The prevention and treatment of Covid-19 and related development during pandemic

Wang¹,

Lee²,

Yeh³

et al. 2021

JFB

View full text Add to dashboard Cite

When the outbreak of human novel coronavirus was first reported in Wuhan, China at the end of 2019, the epidemic spread rapidly around the world and finally became a pandemic in 2020. In order to seek effective drugs to treat the Covid-19 infected patients for emergent use and for the disease prevention, researchers examined numerous existed antiviral drugs that may have the potential for Covid-19 treatment. At the same time, antibody treatment and vaccines development were ongoing simultaneously. The aim of this review is to introduce antibody therapy, vaccine development and potential antiviral treatments on Covid-19 and to discuss the future perspective on the Covid-19 pandemic.

show abstract

Severe Acute Respiratory Syndrome Coronavirus 2–Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience

Cited by 8 publications

References 3 publications

Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience

Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience

COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments

The prevention and treatment of Covid-19 and related development during pandemic

Contact Info

Product

Resources

About